home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409a.zip
/
M9490045.TXT
< prev
next >
Wrap
Text File
|
1994-09-03
|
3KB
|
45 lines
Document 0045
DOCN M9490045
TI Recommendations of the U.S. Public Health Service Task Force on the use
of zidovudine to reduce perinatal transmission of human immunodeficiency
virus.
DT 9411
SO MMWR Morb Mortal Wkly Rep. 1994 Aug 5;43(RR-11):1-20. Unique Identifier
: AIDSLINE MED/94322749
AB These recommendations update the interim guidelines (1) developed by the
U.S. Public Health Service for the use of zidovudine (ZDV) to reduce the
risk for perinatal transmission of human immunodeficiency virus (HIV)
infection. The recently reported results of AIDS Clinical Trials Group
Protocol 076 demonstrated that ZDV administered to a selected group of
HIV-infected pregnant women and their infants can reduce the risk for
perinatal HIV transmission by approximately two-thirds. The regimen used
in this trial included antenatal oral administration of ZDV beginning at
14-34 weeks of gestation and continuing throughout pregnancy, followed
by intrapartum intravenous ZDV and postnatal oral administration of ZDV
to the infant for 6 weeks after delivery. This document summarizes the
results of the trial, discusses limitations in the interpretation of the
results, reviews the potential long-term adverse effects of this ZDV
regimen for infants and women, and provides recommendations for the use
of ZDV to reduce perinatal transmission and for medical monitoring of
pregnant women and infants receiving this therapy. Because the clinical
status of many HIV-infected women may differ from that of the women in
this trial, the recommendations should be tailored to each woman's
clinical situation. The potential benefits, unknown long-term effects,
and gaps in knowledge about her specific clinical situation must be
discussed with the woman. This information is intended to provide a
basis for discussion between the woman and her healthcare provider so
that the woman can weigh the risks and benefits of such therapy and make
informed decisions about her treatment.
DE Adult Drug Administration Schedule Female Fetal Monitoring
Gestational Age Hematologic Tests Human HIV
Infections/CONGENITAL/DRUG THERAPY/*PREVENTION & CONTROL/ TRANSMISSION
Infant Infant, Newborn Leukocyte Count Pregnancy Pregnancy
Complications, Infectious/*DRUG THERAPY *Prenatal Exposure Delayed
Effects Randomized Controlled Trials T4 Lymphocytes
Zidovudine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE
GUIDELINE JOURNAL ARTICLE PRACTICE GUIDELINE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).